Patents by Inventor Shinsuke INUKI

Shinsuke INUKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compound or salt thereof, natural killer T cell activator, and pharmaceutical composition
    Patent number: 10919926
    Abstract: Problems of the present invention is to provide a novel compound or a salt thereof capable of activating natural killer T cell, a natural killer T cell activating agent containing such a compound or a salt thereof, and a pharmaceutical composition. The compound of the present invention is a compound represented by the following formula (1) or a salt thereof. It is preferable that total carbon number of the number of carbon atoms in the monovalent hydrocarbon group in R1 in the formula (1) excluding a sustitutent and the number of carbon atoms in the divalent hydrocarbon group in X1 is 5 to 50. The natural killer T cell activating agent contains the aforementioned compound or a salt thereof. The pharmaceutical composition contains the aforementioned compound or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: February 16, 2021
    Assignees: KEIO UNIVERSITY, REGiMMUNE CORPORATION
    Inventors: Shinsuke Inuki, Natsumi Hirata, Emi Kashiwabara, Junichiro Kishi, Toshihiko Aiba, Yukari Fujimoto
  • COMPOUND OR SALT THEREOF, NATURAL KILLER T CELL ACTIVATOR, AND PHARMACEUTICAL COMPOSITION
    Publication number: 20200207798
    Abstract: The invention provides a compound or a salt thereof capable of activating natural killer T cell, a natural killer T cell activating agent containing such a compound or a salt thereof, and a pharmaceutical composition. The compound of the invention is a compound represented by the following formula (1) or a salt thereof. It is preferable that total carbon number of the number of carbon atoms in the monovalent hydrocarbon group in R1 in the formula (1) excluding a substitutent and the number of carbon atoms in the divalent hydrocarbon group in X1 is 5 to 50. The natural killer T cell activating agent contains the aforementioned compound or a salt thereof. The pharmaceutical composition contains the aforementioned compound or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: March 2, 2017
    Publication date: July 2, 2020
    Applicants: KEIO UNIVERSITY, REGiMMUNE CORPORATION
    Inventors: Shinsuke INUKI, Natsumi HIRATA, Emi KASHIWABARA, Junichiro KISHI, Toshihiko AIBA, Yukari FUJIMOTO
  • Nitrogen-containing heterocyclic compound or salt thereof
    Patent number: 9783536
    Abstract: A compound represented by Formula [1](in the formula, Z1 represents N, CH, or the like; X1 represents NH or the like; R1 represents a heteroaryl group or the like; each of R2, R3, and R4 represents a hydrogen atom, a halogen atom, an alkoxy group, or the like; and R5 represents a heteroaryl group or the like) or salt thereof.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: October 10, 2017
    Assignee: FUJIFILM Corporation
    Inventors: Hidetomo Furuyama, Hideki Kurihara, Takahiro Terao, Daisuke Nakagawa, Shintaro Tanabe, Takayuki Kato, Masahiko Yamamoto, Shinichiro Sekine, Tomoyuki Mashiko, Shinsuke Inuki, Satoshi Ueda
  • NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF
    Publication number: 20150322063
    Abstract: A compound represented by Formula [1] (in the formula, Z1 represents N, CH, or the like; X1 represents NH or the like; R1 represents a heteroaryl group or the like; each of R2, R3, and R4 represents a hydrogen atom, a halogen atom, an alkoxy group, or the like; and R5 represents a heteroaryl group or the like) or salt thereof.
    Type: Application
    Filed: July 9, 2015
    Publication date: November 12, 2015
    Applicant: FUJIFILM Corporation
    Inventors: Hidetomo FURUYAMA, Hideki KURIHARA, Takahiro TERAO, Daisuke NAKAGAWA, Shintaro TANABE, Takayuki KATO, Masahiko YAMAMOTO, Shinichiro SEKINE, Tomoyuki MASHIKO, Shinsuke INUKI, Satoshi UEDA
  • Nitrogen-containing heterocyclic compound or salt thereof
    Patent number: 9145415
    Abstract: The object is to provide an Fms-like tyrosine kinase 3 (FLT3) inhibitor useful as a therapeutic agent for acute myeloid leukemia (AML). A novel nitrogen-containing heterocyclic compound represented by the general formula [1] or a salt thereof is provided. The compound or a salt thereof of the present invention can be used as an active ingredient of a pharmaceutical composition for a treatment of a disease or condition relating to FLT3, such as acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL).
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: September 29, 2015
    Assignee: FUJIFILM Corporation
    Inventors: Masaru Takasaki, Toshiaki Tsujino, Shintarou Tanabe, Megumi Ookubo, Kimihiko Sato, Atsush Hirai, Daisuke Terada, Shinsuke Inuki, Shinsuke Mizumoto
  • NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF
    Publication number: 20150045339
    Abstract: The object is to provide an Fms-like tyrosine kinase 3 (FLT3) inhibitor useful as a therapeutic agent for acute myeloid leukemia (AML). A novel nitrogen-containing heterocyclic compound represented by the general formula [1] or a salt thereof is provided. The compound or a salt thereof of the present invention can be used as an active ingredient of a pharmaceutical composition for a treatment of a disease or condition relating to FLT3, such as acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL).
    Type: Application
    Filed: October 16, 2014
    Publication date: February 12, 2015
    Applicant: FUJIFILM CORPORATION
    Inventors: Masaru TAKASAKI, Toshiaki TSUJINO, Shintarou TANABE, Megumi OOKUBO, Kimihiko SATO, Atsushi HIRAI, Daisuke TERADA, Shinsuke INUKI, Shinsuke MIZUMOTO